Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026)
Mirum Pharmaceuticals' quarterly Income from Continuing Operations came in at 790155000.0 in Q1 2026, down 5283.63% year-on-year from 15243282.98 in Q1 2025, and down 13689.79% quarter-over-quarter from 5730000.0 in Q4 2025.
Mirum Pharmaceuticals has reported Income from Continuing Operations for 8 years, with the latest figure at 790155000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 5283.63% year-over-year to 790155000.0; the trailing twelve-month figure through Mar 2026 stood at 798841000.0 (down 932.9% YoY), and the FY2025 full-year result was 23363000.0, up 73.43% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 790155000.0, down from 5730000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2905000.0 in Q3 2025, with the low at 790155000.0 in Q1 2026.
- Average Income from Continuing Operations over 5 years is 70620000.0, with a median of 25279000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations soared 120.41% in 2025 and sank 5283.63% in 2026.
- Tracing MIRM's Income from Continuing Operations over 5 years: stood at 36431000.0 in 2022, then rose by 2.12% to 35659000.0 in 2023, then soared by 33.28% to 23790000.0 in 2024, then jumped by 75.91% to 5730000.0 in 2025, then tumbled by 13689.79% to 790155000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 790155000.0 (Q1 2026), 5730000.0 (Q4 2025), and 2905000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mirum Pharmaceuticals | 5.97 Bn | 5.59 Bn | 131.08 Mn | -790.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.55 Mn |
| Sep 30, 2021 | -47.11 Mn |
| Jun 30, 2021 | -43.89 Mn |
| Mar 31, 2021 | -50.53 Mn |
| Dec 31, 2020 | 66.17 Mn |
| Sep 30, 2020 | -21.51 Mn |
| Jun 30, 2020 | -23.25 Mn |
| Mar 31, 2020 | -21.31 Mn |
| Dec 31, 2019 | -18.07 Mn |
| Sep 30, 2019 | -15.09 Mn |
| Jun 30, 2019 | -13.56 Mn |
| Mar 31, 2019 | -5.96 Mn |